Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) has a beta value of 2.58 and has seen 1.03 million shares traded in the last trading session. The company,
During the last session, Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP)’s traded shares were 0.3 million, with the beta value of the company hitting 2.69. The 52-week
In the last trading session, 1.54 million shares of the Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) were traded, and its beta was 2.75. Most recently the
In the last trading session, 1.21 million Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) shares changed hands as the company’s beta touched 2.44. With the company’s per
In the last trading session, 2.01 million Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) shares changed hands as the company’s beta touched 2.62. With the company’s per
In recent trading session, Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) saw 0.42 million shares changing hands at last check today with its beta currently measuring 2.91.
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) has a beta value of 2.84 and has seen 2.89 million shares traded in the last trading session. The company,
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) has a beta value of 2.79 and has seen 2.96 million shares traded in the last trading session. The company,
During the last session, Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP)’s traded shares were 1.87 million, with the beta value of the company hitting 2.78. At the
During the recent session, Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP)’s traded shares were 0.49 million, with the beta value of the company hitting 2.78. The 52-week
Marketing Sentinel delivers exclusive content, news, articles, and comprehensive coverage of events in the USA and worldwide with a commitment to reliability, objectivity, and timeliness.
© 2024, Powered by Smart TechOne
